Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$2.5B
218M shares
52-week range
$4.90 – $12.85
88% from low
Sector
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Exchange
NASDAQ
CS
Neogen Corp is develop, manufacture and market a diverse line of products and services dedicated to food and animal safety. Its Food Safety segment consists mainly of diagnostic test kits and complementary products (e.g., culture media) sold to food and animal feed producers and processors to preserve the safety and quality of food to prevent contamination and foodborne illnesses such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, and ruminant by-products. These products also ensure the general hygiene of the food manufacturing environment. It also have products to determine food quality and nutritional components. Its segments are Food, Animal safety. Majority of revenue comes from Food Safety. It has presence in United states, and International market.
www.neogen.comNo one on the platform currently holds NEOG.
| Institution | Shares | Reported |
|---|---|---|
| Bridgewater Associatesas of 2026-03-31 | 106,427 | $988.7K |
| Renaissance Technologiesas of 2025-12-31 | 29,539 | $206.5K |
| Execution date | Ratio |
|---|---|
| 2021-06-07 | 2-for-1 |
| 2018-01-02 | 4-for-3 |
| 2013-10-31 | 3-for-2 |
| 2009-12-16 | 3-for-2 |
| 2007-09-05 | 3-for-2 |
No one on the platform has traded NEOG yet.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$NEOG CEO purchased 370 shares at $11.81 for a total of $4,370. Nassif Mikheal now owns 1,074 shares. https://ceo-buys.com
View on StockTwits ↗https://www.marketbeat.com/earnings/reports/2026-7-30-neogen-co-stock/ $NEOG Neogen Earnings Transcript
View on StockTwits ↗$NEOG Q4 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.05 up 98.23% YoY • Reported revenue of $225.3M down -0.07% YoY • Neogen Corporation provides fiscal year 2027 guidance for total revenue in the range of $880 to $885 million and Adjusted EBITDA in the range of approximately $180 to $182 million.
View on StockTwits ↗$NEOG i dont get why this is constantly falling on green days
View on StockTwits ↗$NEOG Share Price: $9.09 Contract Selected: Oct 16, 2026 $10 Calls Buy Zone: $0.77 – $0.95 Target Zone: $1.42 – $1.73 Potential Upside: 75% ROI Time to Expiration: 164 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits ↗$NEOG Current Stock Price: $9.40 Contracts to trade: $10.0 NEOG May 15 2026 Call Entry: $0.10 Exit: $0.14 ROI: 40% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
View on StockTwits ↗$NEOG $9.51 bid. RETAIN POSITION Holding long position at a profit. https://stocktwits.com/G101SPM/message/621483117 BRIEF: Neogen has now successfully completed multiple operational qualifications for certain Petrifilm single kit units . Neogen is planning to host two investor tours of its Petrifilm manufacturing facility in Lansing, Michigan on April 20, 2026 and April 21, 2026. The company is disclosing that it has now successfully completed multiple operational qualifications for certain Petrifilm single kit units (SKUs) and is proceeding forward on multiple performance qualifications for these SKUs as part of its overall validation efforts. This information will be shared with investors during the tours.
View on StockTwits ↗Fundamental analysis of $NEOG (NEOGEN CORP) based on financial data and reported results. #NEOG #NEOGEN
View on StockTwits ↗$NEOG EPS Surprise +125% - Rev Surprise +3% Notes: Neogen beat, quiet https://share.trendspider.com/chart/NEOG/94993uzcu5k?_go=anonmav
View on StockTwits ↗$NEOG reported 0.09 EPS and 211.20 revenue for Q3. http://www.estimize.com/intro/neog?chart=historical&metric_name=eps&utm_content=NEOG&utm
View on StockTwits ↗$NEOG (-9.7% pre) Neogen: Fiscal Q3 Earnings Snapshot https://ooc.bz/l/98350
View on StockTwits ↗$NEOG Q3 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.08 down -60.00% YoY • Reported revenue of $211.2M down -4.43% YoY • Neogen is increasing its fiscal year 2026 revenue guidance to $857M to $860M, while maintaining its adjusted EBITDA guidance at approximately $175M for the fiscal year.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $880M | +2.6% | $0.29 | $0.24–$0.37 | 40.5× | 2 |
| 2028 | $851M | -3.3% | $0.41 | $0.38–$0.44 | 29.0× | 2 |
| 2029 | $896M | +5.2% | $0.46 | $0.44–$0.48 | 25.8× | 1 |
| 2030 | $965M | +7.7% | $0.50 | $0.48–$0.52 | 23.8× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 5 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-30 | $0.06 | $0.09 | +58.8% |
| 2026-04-09 | $0.04 | $0.09 | +125.0% |
| 2026-01-08 | $0.07 | $0.10 | +42.9% |
| 2025-10-09 | $-0.07 | $0.04 | +154.1% |
| 2025-07-29 | $0.08 | $0.05 | -37.5% |
| 2025-04-09 | $0.13 | $0.10 | -23.1% |
| 2025-01-10 | $0.09 | $0.11 | +22.2% |
| 2024-10-10 | $0.09 |
| $0.07 |
| -17.6% |
| $1.6B |
| — |
| NTLAIntellia Therapeutics, Inc. | $11.83 | -2.15% | $1.7B | — |
| NVCRNovocure Ltd | $17.38 | -1.19% | $2.0B | — |
Source: Financial Modeling Prep · peers by sector/industry